[关键词]
[摘要]
糖尿病视网膜病变(DR)是导致糖尿病患者视力丧失的首要原因。目前抗血管内皮生长因子(VEGF)疗法存在部分患者应答不足和需反复注射的局限性，因此探索新的治疗靶点至关重要。血管生成素样蛋白4(ANGPTL4)是一种多功能分泌蛋白，在DR病理进程中发挥关键调控作用，被视为极具潜力的干预靶点。文章系统阐述了ANGPTL4的生物学特性，重点探讨其在DR发生发展中的表达变化、分子机制及网络调控作用，并对以ANGPTL4为靶点的治疗策略进行展望，旨在为DR的机制解析、多靶点药物开发及临床防治提供新的思路与方向。
[Key word]
[Abstract]
Diabetic retinopathy(DR)remains the leading cause of vision loss in patients with diabetes. Current anti-vascular endothelial growth factor(VEGF)therapies are limited by inadequate response in some patients and the necessity for repeated intravitreal injections, underscoring the urgent need for novel therapeutic targets. Angiopoietin-like protein 4(ANGPTL4), a multifunctional secreted protein, has emerged as a critical regulator in the pathogenesis and progression of DR, positioning it as a promising interventional target. This review systematically elaborates the biological characteristics of ANGPTL4, with a focus on its expression dynamics, molecular mechanisms, and regulatory networks rolesin the development of DR. Furthermore, the prospects of ANGPTL4-targeted therapeutic strategies are discussed, aiming to offer new insights and directions for understanding DR pathogenesis, advancing multi-target drug development, and improving clinical management.
[中图分类号]
[基金项目]
国家自然科学基金项目(No.82560206); 朗视界·沐光明中青年眼科科研项目(No.BCF-KH-YK-20240906-02)
